The meningitis debacle is going to harm all compounding pharmacies, even those with impeccable service. I wonder if the business model per se will be able to survive. From today’s NYT: http://www.nytimes.com/2012/10/07/us/scant-drug-maker-oversight-in-meningitis-outbreak.html